These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 1864816

  • 1. Sickle cell vaso-occlusion.
    Fabry ME, Kaul DK.
    Hematol Oncol Clin North Am; 1991 Jun; 5(3):375-98. PubMed ID: 1864816
    [Abstract] [Full Text] [Related]

  • 2. Erythrocyte adhesion in sickle cell disease.
    Parise LV, Telen MJ.
    Curr Hematol Rep; 2003 Mar; 2(2):102-8. PubMed ID: 12901140
    [Abstract] [Full Text] [Related]

  • 3. Rheological studies of erythrocyte-endothelial cell interactions in sickle cell disease.
    Barabino GA, McIntire LV, Eskin SG, Sears DA, Udden M.
    Prog Clin Biol Res; 1987 Mar; 240():113-27. PubMed ID: 3615482
    [Abstract] [Full Text] [Related]

  • 4. Sickle erythrocyte adherence to endothelium at low shear: role of shear stress in propagation of vaso-occlusion.
    Montes RA, Eckman JR, Hsu LL, Wick TM.
    Am J Hematol; 2002 Jul; 70(3):216-27. PubMed ID: 12111767
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea.
    Cartron JP, Elion J.
    Transfus Clin Biol; 2008 Jul; 15(1-2):39-50. PubMed ID: 18515167
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N.
    Pediatr Nurs; 2006 Jul; 32(6):541-3. PubMed ID: 17256291
    [Abstract] [Full Text] [Related]

  • 9. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.
    Manwani D, Frenette PS.
    Hematology Am Soc Hematol Educ Program; 2013 Jul; 2013():362-9. PubMed ID: 24319205
    [Abstract] [Full Text] [Related]

  • 10. Cellular and rheological factors contributing to sickle cell microvascular occlusion.
    Kurantsin-Mills J, Lessin LS.
    Blood Cells; 1986 Jul; 12(1):249-70. PubMed ID: 3790735
    [Abstract] [Full Text] [Related]

  • 11. The delay time in sickle cell disease after 40 years: A paradigm assessed.
    Ferrone FA.
    Am J Hematol; 2015 May; 90(5):438-45. PubMed ID: 25645011
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology.
    Stuart MJ, Setty BN.
    Pediatr Pathol Mol Med; 2001 May; 20(1):27-46. PubMed ID: 12673843
    [Abstract] [Full Text] [Related]

  • 15. Sickle cell vaso-occlusion.
    Chiang EY, Frenette PS.
    Hematol Oncol Clin North Am; 2005 Oct; 19(5):771-84, v. PubMed ID: 16214643
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT, de Lucena Angulo I, Vianna Bonini Palma P, Zago MA.
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [Abstract] [Full Text] [Related]

  • 19. [Pathophysiology and treatment of sickle-cell disease].
    van Beers EJ, Peters M, Biemond BJ.
    Ned Tijdschr Geneeskd; 2005 May 21; 149(21):1144-9. PubMed ID: 15940917
    [Abstract] [Full Text] [Related]

  • 20. Adherent leukocytes capture sickle erythrocytes in an in vitro flow model of vaso-occlusion.
    Finnegan EM, Turhan A, Golan DE, Barabino GA.
    Am J Hematol; 2007 Apr 21; 82(4):266-75. PubMed ID: 17094094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.